^
Association details:
| Biomarker: | MSH6 mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Regression of chemotherapy-resistant Polymerase e (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab
Excerpt:
Patient # 1 harbored an ultra-mutated (Mutation Load/MB = 117.3, total mutations = 4660) tumor driven by mutation in the exonuclease domain of the DNA polymerase ε gene. Patient # 2 harbored a hyper-mutated tumor (Mutation Load/MB = 33.5, total mutations = 1037) due to a germinal MSH6 gene mutation. Both patients demonstrated a remarkable clinical response to the anti-PD1 immune check-point inhibitor nivolumab.
DOI:
10.1158/1078-0432.CCR-16-1031
